AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33136781 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 32970558 — intervention group
Group type: EXPERIMENTAL
Intervention: Barrier enclosure
Number of subjects: 50
Study 32970558 — intervention group
Group type: COMPARATOR
Intervention: No barrier
Number of subjects: 50
Study 32970558 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice barrier enclosure
Number of subjects: 50
Study 34478381 — intervention group
Group type: EXPERIMENTAL
Intervention: Block-local circular convolution binding
Number of subjects: 0
Study 34478381 — intervention group
Group type: EXPERIMENTAL
Intervention: Random projection based binding
Number of subjects: 0
Study 33263183 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated body mass index (BMI)
Number of subjects: 0
Study 33263183 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 34672847 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirabegron 50 mg
Number of subjects: 110
Study 34672847 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 32593592 — intervention group
Group type: EXPERIMENTAL
Intervention: Thromboembolic prophylaxis
Number of subjects: 72
Study 32593592 — intervention group
Group type: COMPARATOR
Intervention: Not starting medication
Number of subjects: 72
Study 35729762 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose FIO₂ of 30%, 40%, 50%, and 100% (Arm 1)
Number of subjects: 26
Study 35729762 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose FIO₂ of 60%, 70%, 80%, and 100% (Arm 2)
Number of subjects: 26
Study 35729762 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% FIO₂ (both Arm 1 and Arm 2)
Number of subjects: 26
Study 32721210 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate Bronchial Thermoplasty (BT) treatment (n=20)
Number of subjects: 40
Study 32721210 — intervention group
Group type: COMPARATOR
Intervention: Delayed control group (n=20)
Number of subjects: 40
Study 32792131 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine (0.25%)
Number of subjects: 14
Study 32792131 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% saline)
Number of subjects: 14
Study 36047578 — intervention group
Group type: EXPERIMENTAL
Intervention: The Growth Factory (TGF) intervention
Number of subjects: 119
Study 36047578 — intervention group
Group type: COMPARATOR
Intervention: Passive control group
Number of subjects: 119
Study 33044490 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-taken pooled samples
Number of subjects: 1793
Study 33044490 — intervention group
Group type: COMPARATOR
Intervention: Clinician triple samples
Number of subjects: 1793
Study 33044490 — intervention group
Group type: COMPARATOR
Intervention: Vulvovaginal swabs (VVS) and first-catch urine (FCU) testing alone
Number of subjects: 1793
Study 34234141 — intervention group
Group type: EXPERIMENTAL
Intervention: cfSNV method for detecting low-frequency mutations from cfDNA
Number of subjects: 0
Study 34234141 — intervention group
Group type: EXPERIMENTAL
Intervention: cfSNV method
Number of subjects: 0
Study 34234141 — intervention group
Group type: EXPERIMENTAL
Intervention: cfSNV tumor mutation profile from cfDNA WES data
Number of subjects: 0
Study 33099503 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-loop decision support system
Number of subjects: 0
Study 33099503 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 0
Study 33201085 — intervention group
Group type: EXPERIMENTAL
Intervention: EQ-5D 3L value set
Number of subjects: 0
Study 33201085 — intervention group
Group type: EXPERIMENTAL
Intervention: EQ-5D 5L value set
Number of subjects: 0
Study 35533737 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT)
Number of subjects: 40
Study 35533737 — intervention group
Group type: COMPARATOR
Intervention: Aerobic exercise training
Number of subjects: 40
Study 34563277 — intervention group
Group type: EXPERIMENTAL
Intervention: Matrix-M-adjuvanted quadrivalent nanoparticle influenza vaccine (qNIV)
Number of subjects: 2654
Study 34563277 — intervention group
Group type: COMPARATOR
Intervention: Quadrivalent inactivated influenza vaccine (IIV4)
Number of subjects: 2654
Study 32057673 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose HCG from Day 7 until at least three follicles reached 17 mm or more
Number of subjects: 105
Study 32057673 — intervention group
Group type: COMPARATOR
Intervention: Conventional ovarian stimulation with highly purified HMG injections
Number of subjects: 105
Study 34130595 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing
Number of subjects: 255
Study 34130595 — intervention group
Group type: COMPARATOR
Intervention: Health education and brief advice
Number of subjects: 255
Study 32109194 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent rituximab (375 mg/m2) with cladribine (0.15 mg/kg)
Number of subjects: 68
Study 32109194 — intervention group
Group type: COMPARATOR
Intervention: Cladribine monotherapy
Number of subjects: 68
Study 32109194 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed rituximab after cladribine
Number of subjects: 68
Study 36053717 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E 200 IU
Number of subjects: 84
Study 36053717 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin 500 mg
Number of subjects: 84
Study 36053717 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 34376554 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab followed by sipuleucel-T (Arm 1)
Number of subjects: 37
Study 34376554 — intervention group
Group type: EXPERIMENTAL
Intervention: Sipuleucel-T followed by atezolizumab (Arm 2)
Number of subjects: 37
Study 616119287 — intervention group
Group type: EXPERIMENTAL
Intervention: Retixoft (300 mg alpha-lipoic acid, 1.1 mg vitamin B1, 1.4 mg vitamin B2, 25 mg rutoside) for 3 months
Number of subjects: 80
Study 616119287 — intervention group
Group type: COMPARATOR
Intervention: No Retixoft supplementation (Control)
Number of subjects: 80
Study 34348079 — intervention group
Group type: EXPERIMENTAL
Intervention: mRPQ (modified Rivermead Post-concussion Symptoms Questionnaire)
Number of subjects: 298
Study 34329333 — intervention group
Group type: EXPERIMENTAL
Intervention: Informal provider as first contact
Number of subjects: 255
Study 34329333 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss as a presenting symptom
Number of subjects: 255
Study 34329333 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatigue as a presenting symptom
Number of subjects: 255
Study 34329333 — intervention group
Group type: EXPERIMENTAL
Intervention: Underweight BMI category
Number of subjects: 255
Study 34329333 — intervention group
Group type: EXPERIMENTAL
Intervention: Good knowledge about TB
Number of subjects: 255
Study 32942102 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid chromatography quadrupole time‐of‐flight mass spectrometry method for tryptophan and kynurenine determination
Number of subjects: 0
Study 32942102 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid chromatography quadrupole time‐of‐flight mass spectrometry method
Number of subjects: 0
Study 36400636 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-centered communication
Number of subjects: 108
Study 34049484 — intervention group
Group type: EXPERIMENTAL
Intervention: Galcanezumab 120 mg
Number of subjects: 1773
Study 34049484 — intervention group
Group type: EXPERIMENTAL
Intervention: Galcanezumab 240 mg
Number of subjects: 1773
Study 34049484 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1773
Study 34049484 — intervention group
Group type: EXPERIMENTAL
Intervention: Galcanezumab 120 mg and 240 mg
Number of subjects: 1773
Study 32723736 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) counselling sessions, approximately 10 sessions (4 in-person with Ped/NP and up to 6 telephonic with a trained RD) over about 2 years.
Number of subjects: 24
Study 32723736 — intervention group
Group type: COMPARATOR
Intervention: Usual care (training in billing/coding and study procedures only).
Number of subjects: 24
Study 36145549 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5583
Study 34672925 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented Reality Exposure Therapy (ARET)
Number of subjects: 25
Study 34672925 — intervention group
Group type: COMPARATOR
Intervention: Waitlist Control
Number of subjects: 25
Study 34672925 — intervention group
Group type: EXPERIMENTAL
Intervention: ARET
Number of subjects: 25
Study 35979404 — intervention group
Group type: EXPERIMENTAL
Intervention: Dog-assisted intervention
Number of subjects: 169
Study 35979404 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation intervention
Number of subjects: 169
Study 35979404 — intervention group
Group type: COMPARATOR
Intervention: No treatment control group
Number of subjects: 169
Study 32542878 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct Oral Anticoagulants (DOACs)
Number of subjects: 959
Study 32542878 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K Antagonists (VKAs)
Number of subjects: 959
Study 32542878 — intervention group
Group type: COMPARATOR
Intervention: No anticoagulation
Number of subjects: 959
Study 35588200 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients enrolled during COVID-19 (n=191)
Number of subjects: 856
Study 35588200 — intervention group
Group type: COMPARATOR
Intervention: Patients enrolled pre-COVID-19 (n=665)
Number of subjects: 856
Study 35588200 — intervention group
Group type: EXPERIMENTAL
Intervention: Unmarried patients during COVID-19
Number of subjects: 856
Study 35588200 — intervention group
Group type: COMPARATOR
Intervention: Unmarried patients pre-COVID-19
Number of subjects: 856
Study 35568336 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser peripheral iridotomy (LPI) in one randomly selected eye
Number of subjects: 889
Study 35568336 — intervention group
Group type: COMPARATOR
Intervention: Untreated control (fellow eye)
Number of subjects: 889
Study 33538822 — intervention group
Group type: EXPERIMENTAL
Intervention: Firearm involvement during adolescence (use, access, victimization)
Number of subjects: 1829
Study 33538822 — intervention group
Group type: EXPERIMENTAL
Intervention: Victimization (threatened with a weapon or gunshot injury) during adolescence
Number of subjects: 1829
Study 33538822 — intervention group
Group type: EXPERIMENTAL
Intervention: Victimization (gunshot injury) during adolescence
Number of subjects: 1829
Study 33538822 — intervention group
Group type: EXPERIMENTAL
Intervention: Firearm involvement during adolescence
Number of subjects: 1829
Study 36167553 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 78
Study 36167553 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 78
Study 32564066 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILI)
Number of subjects: 4859
Study 32564066 — intervention group
Group type: COMPARATOR
Intervention: Diabetes support and education (DSE)
Number of subjects: 4859
Study 32160798 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral group intervention
Number of subjects: 38
Study 32160798 — intervention group
Group type: COMPARATOR
Intervention: Active waiting time protocol (Control)
Number of subjects: 38
Study 35114384 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone initiation
Number of subjects: 621171
Study 35114384 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone initiators
Number of subjects: 621171
Study 33713622 — intervention group
Group type: EXPERIMENTAL
Intervention: HaRT-A plus XR-NTX
Number of subjects: 308
Study 33713622 — intervention group
Group type: EXPERIMENTAL
Intervention: HaRT-A plus placebo
Number of subjects: 308
Study 33713622 — intervention group
Group type: EXPERIMENTAL
Intervention: HaRT-A alone
Number of subjects: 308
Study 33713622 — intervention group
Group type: COMPARATOR
Intervention: services-as-usual control
Number of subjects: 308
Study 35264104 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS (transcutaneous electrical nerve stimulation) applied with a pulse width of 385 μs and a frequency of 10 Hz for 30 min.
Number of subjects: 30
Study 35264104 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment without stimulation.
Number of subjects: 30
Study 33813536 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation program (four-scenario simulation)
Number of subjects: 43
Study 33813536 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 43
Study 36239289 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval-walking training (IWT)
Number of subjects: 55
Study 36239289 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-intervention)
Number of subjects: 55
Study 35896768 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted Temperature Management (TTM) at 33 °C
Number of subjects: 950
Study 35896768 — intervention group
Group type: COMPARATOR
Intervention: Targeted Temperature Management (TTM) at 36 °C
Number of subjects: 950
Study 35896768 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedation and analgesia dosing and titration
Number of subjects: 950
Study 32838539 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth cognitive behavioral therapy for insomnia (CBT‐CI)
Number of subjects: 0
Study 32962677 — intervention group
Group type: EXPERIMENTAL
Intervention: Autonomy supportive intervention delivered by PE teachers
Number of subjects: 502
Study 35576853 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Thai massage (TTM)
Number of subjects: 78
Study 35576853 — intervention group
Group type: COMPARATOR
Intervention: Thai boxing exercise (TBE)
Number of subjects: 78
Study 33768520 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral misoprostol
Number of subjects: 1213
Study 32584425 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiparasitic treatment with albendazole
Number of subjects: 0
Study 32584425 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 35536347 — intervention group
Group type: EXPERIMENTAL
Intervention: Voice-based delivery system of the PHQ 9 using Amazon Alexa
Number of subjects: 41
Study 35536347 — intervention group
Group type: COMPARATOR
Intervention: Paper version of the PHQ 9
Number of subjects: 41
Study 36346956 — intervention group
Group type: EXPERIMENTAL
Intervention: WBT-lifestyle intervention
Number of subjects: 58
Study 32720469 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine vitamin A supplementation (VAS)
Number of subjects: 855
Study 32720469 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole for deworming
Number of subjects: 855
Study 32720469 — intervention group
Group type: EXPERIMENTAL
Intervention: Complementary feeding practices
Number of subjects: 855
Study 32720469 — intervention group
Group type: EXPERIMENTAL
Intervention: Family planning services
Number of subjects: 855
Study 37352528 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant intensity modulated radiation therapy (18 Gy with fractionated doses of 3 Gy) followed by surgery 4 weeks later
Number of subjects: 60
Study 37352528 — intervention group
Group type: COMPARATOR
Intervention: Upfront surgery
Number of subjects: 60
Study 33808137 — intervention group
Group type: EXPERIMENTAL
Intervention: Wrist stabilization exercise + taping therapy (WSE + TT)
Number of subjects: 45
Study 33808137 — intervention group
Group type: EXPERIMENTAL
Intervention: Wrist stabilization exercise (WSE)
Number of subjects: 45
Study 33808137 — intervention group
Group type: COMPARATOR
Intervention: Control group (passive range of motion exercise)
Number of subjects: 45
Study 36093704 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutritional supplementation (1g fish oil with 500mg DHA, 150mg EPA; 22mg carotenoids including 10mg lutein, 10mg meso-zeaxanthin, 2mg zeaxanthin; 15mg vitamin E)
Number of subjects: 77
Study 36093704 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study 36093704 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutritional supplementation
Number of subjects: 77
Study 33525659 — intervention group
Group type: EXPERIMENTAL
Intervention: ELOVL5‐Mo
Number of subjects: 3
Study 33525659 — intervention group
Group type: COMPARATOR
Intervention: Technical control Mo
Number of subjects: 3
Study 33525659 — intervention group
Group type: COMPARATOR
Intervention: Biological control
Number of subjects: 3
Study 32384502 — intervention group
Group type: EXPERIMENTAL
Intervention: High tone external muscle stimulation therapy (HTEMS)
Number of subjects: 50
Study 32384502 — intervention group
Group type: COMPARATOR
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 50
Study 35217858 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized feedback intervention (PFI) regarding social network presence during drinking occasions
Number of subjects: 338
Study 35217858 — intervention group
Group type: COMPARATOR
Intervention: Control group (no feedback)
Number of subjects: 338
Study 36060231 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in maternal emotion regulation (ER)
Number of subjects: 77
Study 35085038 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole Pelvic Radiation Therapy (WPRT)
Number of subjects: 28724
Study 35085038 — intervention group
Group type: COMPARATOR
Intervention: Prostate-only radiotherapy
Number of subjects: 28724
Study 33413210 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsular tension ring (CTR) implantation
Number of subjects: 42
Study 33413210 — intervention group
Group type: COMPARATOR
Intervention: Control (no CTR implantation)
Number of subjects: 42
Study 32151020 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary fiber intake in patients with NAFLD
Number of subjects: 63
Study 32151020 — intervention group
Group type: EXPERIMENTAL
Intervention: NAFLD patients
Number of subjects: 63
Study 32151020 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 63
Study 35679202 — intervention group
Group type: EXPERIMENTAL
Intervention: web-delivered alcohol-linked attentional bias modification (AtBM)
Number of subjects: 43
Study 35679202 — intervention group
Group type: COMPARATOR
Intervention: sham-training (control)
Number of subjects: 43
Study 34934964 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening group (PSA screening)
Number of subjects: 241234
Study 34934964 — intervention group
Group type: COMPARATOR
Intervention: Control group (no screening)
Number of subjects: 241234
Study 34934964 — intervention group
Group type: EXPERIMENTAL
Intervention: Both arms combined
Number of subjects: 241234
Study 36192092 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic resonance enterography (MRE) features at diagnosis
Number of subjects: 0
Study 32229668 — intervention group
Group type: EXPERIMENTAL
Intervention: VIB (vibration protocol)
Number of subjects: 109
Study 32229668 — intervention group
Group type: EXPERIMENTAL
Intervention: SWI (regular swimming training)
Number of subjects: 109
Study 32229668 — intervention group
Group type: COMPARATOR
Intervention: CON (normoactive controls)
Number of subjects: 109
Study 35725020 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 0
Study 35725020 — intervention group
Group type: COMPARATOR
Intervention: Insulin
Number of subjects: 0
Study 32572100 — intervention group
Group type: EXPERIMENTAL
Intervention: Blended CPR training program (18‐minute e‐learning plus 30‐minute hands‐on)
Number of subjects: 832
Study 32572100 — intervention group
Group type: COMPARATOR
Intervention: Traditional CPR training program
Number of subjects: 832
Study 32572100 — intervention group
Group type: EXPERIMENTAL
Intervention: Blended CPR training program
Number of subjects: 832
Study 33524208 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile application (genitalsystem.apk)
Number of subjects: 63
Study 33524208 — intervention group
Group type: COMPARATOR
Intervention: Standard curriculum (control group)
Number of subjects: 63
Study 34335138 — intervention group
Group type: EXPERIMENTAL
Intervention: Newborn screening for sickle cell disease and trait
Number of subjects: 10529
Study 34335138 — intervention group
Group type: EXPERIMENTAL
Intervention: Newborn screening for alpha thalassemia trait
Number of subjects: 10529
Study 34335138 — intervention group
Group type: EXPERIMENTAL
Intervention: Newborn screening for G6PD deficiency
Number of subjects: 10529
Study 36100406 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory mechanics-guided sedation strategy (dexmedetomidine combined with propofol)
Number of subjects: 90
Study 36100406 — intervention group
Group type: COMPARATOR
Intervention: Light sedation (control group)
Number of subjects: 90
Study 35650559 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation-based medical education (SBME)
Number of subjects: 190
Study 35650559 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation-based medical education combined with behavioural economics (SBME + BE)
Number of subjects: 190
Study 35650559 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 190
Study 33646048 — intervention group
Group type: EXPERIMENTAL
Intervention: Talking head featuring the participant's face
Number of subjects: 228
Study 33646048 — intervention group
Group type: COMPARATOR
Intervention: Talking head featuring a stranger's face
Number of subjects: 228
Study 33646048 — intervention group
Group type: COMPARATOR
Intervention: Audio-only condition
Number of subjects: 228
Study 33646048 — intervention group
Group type: EXPERIMENTAL
Intervention: Pro-AI pitch playback
Number of subjects: 228
Study 33646048 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-AI pitch playback
Number of subjects: 228
Study 33788486 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture + CES
Number of subjects: 200
Study 33788486 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture
Number of subjects: 200
Study 33788486 — intervention group
Group type: COMPARATOR
Intervention: CES
Number of subjects: 200
Study 33788486 — intervention group
Group type: COMPARATOR
Intervention: Medication
Number of subjects: 200
Study 34047722 — intervention group
Group type: EXPERIMENTAL
Intervention: EGDT with ScvO2 monitoring
Number of subjects: 120
Study 34047722 — intervention group
Group type: COMPARATOR
Intervention: EGDT without ScvO2 monitoring
Number of subjects: 120
Study 33162347 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency vibrations with passive self-ligating brackets
Number of subjects: 65
Study 33162347 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency vibrations with conventional brackets
Number of subjects: 65
Study 33162347 — intervention group
Group type: COMPARATOR
Intervention: Control group (no vibrations)
Number of subjects: 65